The spike from 2006 to 2008 was again caused by a surge in government revenue driven by increases in log and mineral prices, enabling real DSIP funds to increase by 403 percent
Exendin-4 differs from human GLP-1 by about 50% of its amino acids, importantly having a glycine instead of alanine at the N-terminus (making it DPP-4 resistant) ( [46] )
Several randomized, controlled clinical trials have shown that this drug is effective in reducing pain and fatigue and improving sleep quality (increased slow-wave sleep duration and decreased night-time awakenings)
Most of centella's magic comes from the four big compounds (Asiaticoside, Madecassoside, Asiatic Acid, and Madecassic Acid)
This perspective also exposes the limits of many current designs
GLP-1 agonist drug sales increased 58.2% between December 2022 and December 2023, with Ozempic and Mounjaro driving most of that growth volume